-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Nipah -X- _ O
virus -X- _ O
( -X- _ O
NiV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
highly -X- _ O
pathogenic -X- _ O
zoonotic -X- _ O
agent -X- _ O
in -X- _ O
the -X- _ O
family -X- _ O
Paramyxoviridae -X- _ O
that -X- _ O
is -X- _ O
maintained -X- _ O
in -X- _ O
nature -X- _ O
by -X- _ O
bats. -X- _ O
Outbreaks -X- _ O
have -X- _ O
occurred -X- _ O
in -X- _ O
Malaysia -X- _ O
, -X- _ O
Singapore -X- _ O
, -X- _ O
India -X- _ O
, -X- _ O
and -X- _ O
Bangladesh -X- _ O
and -X- _ O
have -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
40 -X- _ O
to -X- _ O
75 -X- _ O
% -X- _ O
case -X- _ O
fatality -X- _ O
rates. -X- _ O
There -X- _ O
are -X- _ O
currently -X- _ O
no -X- _ O
vaccines -X- _ O
or -X- _ O
postexposure -X- _ O
treatments -X- _ O
licensed -X- _ O
for -X- _ O
combating -X- _ O
human -X- _ O
NiV -X- _ O
infection. -X- _ O
METHODS -X- _ O
AND -X- _ O
RESULTS -X- _ O
: -X- _ O
Four -X- _ B-Patient
groups -X- _ I-Patient
of -X- _ I-Patient
ferrets -X- _ I-Patient
received -X- _ O
a -X- _ O
single -X- _ B-Intervention
vaccination -X- _ I-Intervention
with -X- _ I-Intervention
different -X- _ I-Intervention
recombinant -X- _ I-Intervention
vesicular -X- _ I-Intervention
stomatitis -X- _ I-Intervention
virus -X- _ I-Intervention
vectors -X- _ I-Intervention
expressing -X- _ I-Intervention
: -X- _ O
Group -X- _ B-Comparison
1 -X- _ I-Comparison
, -X- _ I-Comparison
control -X- _ I-Comparison
with -X- _ I-Comparison
no -X- _ I-Comparison
glycoprotein -X- _ I-Comparison
; -X- _ O
Group -X- _ B-Intervention
2 -X- _ I-Intervention
, -X- _ I-Intervention
the -X- _ I-Intervention
NiV -X- _ I-Intervention
fusion -X- _ I-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
F -X- _ I-Intervention
) -X- _ I-Intervention
; -X- _ I-Intervention
Group -X- _ I-Intervention
3 -X- _ I-Intervention
, -X- _ I-Intervention
the -X- _ I-Intervention
NiV -X- _ I-Intervention
attachment -X- _ I-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
G -X- _ I-Intervention
) -X- _ I-Intervention
; -X- _ I-Intervention
and -X- _ I-Intervention
Group -X- _ I-Intervention
4 -X- _ I-Intervention
, -X- _ I-Intervention
a -X- _ I-Intervention
combination -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
NiV -X- _ I-Intervention
F -X- _ I-Intervention
and -X- _ I-Intervention
G -X- _ I-Intervention
proteins. -X- _ I-Intervention
Animals -X- _ O
were -X- _ O
challenged -X- _ O
intranasally -X- _ O
with -X- _ O
NiV -X- _ O
28 -X- _ O
days -X- _ O
after -X- _ O
vaccination. -X- _ O
Control -X- _ B-Outcome
ferrets -X- _ I-Outcome
in -X- _ I-Outcome
Group -X- _ I-Outcome
1 -X- _ I-Outcome
showed -X- _ I-Outcome
characteristic -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
of -X- _ I-Outcome
NiV -X- _ I-Outcome
disease -X- _ I-Outcome
including -X- _ I-Outcome
respiratory -X- _ I-Outcome
distress -X- _ I-Outcome
, -X- _ I-Outcome
neurological -X- _ I-Outcome
disorders -X- _ I-Outcome
, -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
blood -X- _ I-Outcome
and -X- _ I-Outcome
tissues -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
gross -X- _ I-Outcome
lesions -X- _ I-Outcome
and -X- _ I-Outcome
antigen -X- _ I-Outcome
in -X- _ I-Outcome
target -X- _ I-Outcome
tissues -X- _ I-Outcome
; -X- _ I-Outcome
all -X- _ I-Outcome
animals -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
group -X- _ I-Outcome
succumbed -X- _ I-Outcome
to -X- _ I-Outcome
infection -X- _ I-Outcome
by -X- _ I-Outcome
day -X- _ I-Outcome
8. -X- _ I-Outcome
Importantly -X- _ I-Outcome
, -X- _ I-Outcome
all -X- _ I-Outcome
specifically -X- _ I-Outcome
vaccinated -X- _ I-Outcome
ferrets -X- _ I-Outcome
in -X- _ I-Outcome
Groups -X- _ I-Outcome
2-4 -X- _ I-Outcome
showed -X- _ I-Outcome
no -X- _ I-Outcome
evidence -X- _ I-Outcome
of -X- _ I-Outcome
clinical -X- _ I-Outcome
illness -X- _ I-Outcome
and -X- _ I-Outcome
survived -X- _ I-Outcome
challenged. -X- _ I-Outcome
All -X- _ I-Outcome
animals -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
groups -X- _ I-Outcome
developed -X- _ I-Outcome
anti-NiV -X- _ I-Outcome
F -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
G -X- _ I-Outcome
IgG -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
titers. -X- _ I-Outcome
While -X- _ I-Outcome
NiV -X- _ I-Outcome
RNA -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
blood -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
6 -X- _ I-Outcome
post -X- _ I-Outcome
challenge -X- _ I-Outcome
in -X- _ I-Outcome
animals -X- _ I-Outcome
from -X- _ I-Outcome
Groups -X- _ I-Outcome
2-4 -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
orders -X- _ I-Outcome
of -X- _ I-Outcome
magnitude -X- _ I-Outcome
lower -X- _ I-Outcome
than -X- _ I-Outcome
animals -X- _ I-Outcome
from -X- _ I-Outcome
control -X- _ I-Outcome
Group -X- _ I-Outcome
1. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
These -X- _ O
data -X- _ O
show -X- _ O
protective -X- _ B-Outcome
efficacy -X- _ I-Outcome
against -X- _ I-Outcome
NiV -X- _ I-Outcome
in -X- _ O
a -X- _ O
relevant -X- _ O
model -X- _ O
of -X- _ O
human -X- _ O
infection. -X- _ O
Further -X- _ O
development -X- _ O
of -X- _ O
this -X- _ O
technology -X- _ O
has -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
yield -X- _ O
effective -X- _ O
single -X- _ O
injection -X- _ O
vaccines -X- _ O
for -X- _ O
NiV -X- _ O
infection -X- _ O
. -X- _ O

